- Two abstracts on SAR443579 (IPH6101), ANKET® platform lead
asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under
development by partner Sanofi in blood cancer
- Two abstracts on IPH6501, Innate’s second generation ANKET®
for the treatment of relapsed or refractory CD20-expressing B-cell
Non-Hodgkin's Lymphomas
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) announced today that four
abstracts with Innate’s drug candidates have been accepted for the
European Association of Hematology (EHA) 2024 Congress, taking
place June 13-16, 2024 in Madrid, Spain.
- Two abstracts are related to SAR443579 (IPH6101), an
investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager
from a joint research collaboration between Innate Pharma and
Sanofi and currently being evaluated as a monotherapy in a
Sanofi-sponsored Phase 1/2 clinical trial for the treatment of
blood cancers with high unmet needs.
- Two abstracts are related to IPH6501, Innate’s second
generation ANKET® for the treatment of relapsed or refractory
CD20-expressing B-cell Non-Hodgkin's Lymphoma, currently in Phase
1/2 clinical trial.
“We’re pleased to see a continued momentum around our ANKET®
platform assets, SAR443579 and IPH6501,” said Dr. Sonia
Quaratino, Chief Medical Officer of Innate Pharma. “With their
innovative format, we believe that NK Cell Engagers will benefit
for patients who are in high unmet medical need, and we look
forward to continue the studies with these assets.”
EHA abstract details:
SAR443579 / IPH6101 (under development
by Sanofi)
Abstract: S146 Abstract Title:
Completed dose-escalation from the First-in-Human, Phase 1/2 Study
of CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute
Myeloid Leukemia or High Risk-Myelodysplasia Abstract type:
Oral Presentation
Abstract: P475 Abstract Title:
Exploring Dose-response Relationship of a Novel CD123 NK Cell
Engager SAR443579 in Acute Myeloid Leukemia (AML) Models
Abstract type: Poster Presentation
IPH6501
Abstract: P1251 Abstract Title:
Preclinical assessment of IPH6501, a first-in-class IL2V-armed
tetraspecific NK Cell Engager directed against CD20 for R/R B-NHL,
in comparison with a CD20-targeting T Cell Engager Abstract
type: Poster Presentation This abstract is embargoed until
23.05.2024 23:00 CEST, until publication by the American Society of
Clinical Oncology, Inc. for their 2024 ASCO Annual Meeting.
The Abstract PB3041, “A Phase 1/2 trial
investigating safety, tolerability, and preliminary antitumor
activity of IPH6501, a first-in-class NK Cell Engager, in patients
with R/R CD20-expressing NHL” will be available in the EHA
abstracts book.
About ANKET®
ANKET® (Antibody-based NK cell Engager
Therapeutics) is Innate's proprietary platform for
developing next-generation, multi-specific natural killer (NK) cell
engagers to treat certain types of cancer. This versatile,
fit-for-purpose technology is creating an entirely new class of
molecules to induce synthetic immunity against cancer.
About IPH6501
IPH6501 is the first Antibody-based NK cell Engager Therapeutic
to co-engage activating receptors on NK cells (NKp46 and CD16),
IL-2R (but not α subunit) through a variant of human IL-2, and a
tumor antigen (CD20) via a single molecule, hence providing
proliferation and activation signals targeted to NK cells and
promoting their cytotoxic activity against CD20 expressing
malignant cells. IPH6501 has shown better anti-tumor efficacy than
approved benchmark antibodies in preclinical tumor models (Demaria,
EHA 2023).
About the Innate-Sanofi research collaboration and licensing
agreements
The Company has a research collaboration and license agreement
with Sanofi to apply Innate’s proprietary technology to the
development of innovative multi-specific antibody formats engaging
NK cells through the activating receptors NKp46 and CD16 to kill
tumor cells.
Under the terms of the 2016 research collaboration and license
agreement, Sanofi is responsible for the development, manufacturing
and commercialization of products resulting from the research
collaboration, which includes SAR443579/IPH6101 (Trifunctional
anti-CD123 NKp46xCD16 NK cell engager) and SAR445514/IPH6401
(Trifunctional anti-BCMA NKp46xCD16 NK cell engager). As part of
the 2016 agreement, Innate Pharma is eligible to up to €400m in
development and commercial milestone payments as well as royalties
on net sales.
As part of the license agreement entered in December 2022,
Sanofi licensed IPH62 and IPH67 and has the option for one
additional target. Under the terms of the 2022 agreement, Innate
Pharma is eligible to up to €1.35bn in development and commercial
milestone payments as well as royalties on net sales.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on X and LinkedIn.
Information about Innate Pharma shares
ISIN code Ticker code
LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2023,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514484777/en/
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr Media
Relations NewCap Arthur Rouillé Tel.: +33 (0)1 44
71 00 15 innate@newcap.eu
Grafico Azioni Innate Pharma (NASDAQ:IPHA)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Innate Pharma (NASDAQ:IPHA)
Storico
Da Dic 2023 a Dic 2024
